STAT+: Summit shows mixed results from key study of lung cancer drug
Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head study, produced mixed results in a new trial.
Summit Therapeutics said Friday that its closely tracked PD1-VEGF antibody ivonescimab delayed the progression of lung cancer in patients from the U.S. and other Western countries consistent with prior results reported from patients enrolled from China, achieving the goal of a Phase 3 clinical trial.
But ivonescimab has not yet demonstrated a survival benefit for any patients in the study, possibly delaying the company’s ability to file for approval with the Food and Drug Administration and jeopardizing the drug’s blockbuster potential.
Summit shares were flat in early Friday trading.
